{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:41:08Z","timestamp":1769312468570,"version":"3.49.0"},"reference-count":270,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54 GM128729"],"award-info":[{"award-number":["U54 GM128729"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.<\/jats:p>","DOI":"10.3390\/ijms21238989","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T09:04:15Z","timestamp":1606381455000},"page":"8989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["RAGE Signaling in Melanoma Tumors"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-4876","authenticated-orcid":false,"given":"Olamide T.","family":"Olaoba","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sultan","family":"Kadasah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-2909","authenticated-orcid":false,"given":"Stefan W.","family":"Vetter","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Leclerc","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","unstructured":"Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2020). SEER Cancer Statistics Review, 1975\u20132017, National Cancer Institute."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/635203","article-title":"Melanoma: From Melanocyte to Genetic Alterations and Clinical Options","volume":"2013","author":"Bertolotto","year":"2013","journal-title":"Scientifica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.det.2007.04.001","article-title":"The Melanocyte and the Epidermal Melanin Unit: An Expanded Concept","volume":"25","author":"Nordlund","year":"2007","journal-title":"Dermatol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1357-2725(97)00013-7","article-title":"Melanin","volume":"29","author":"Riley","year":"1997","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0749.1988.tb00421.x","article-title":"Extra-Cutaneous Melanin","volume":"1","author":"Breathnach","year":"1988","journal-title":"Pigment. Cell Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-018-0733-7","article-title":"Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fonc.2015.00183","article-title":"Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets","volume":"5","author":"Palmieri","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"adv00139","DOI":"10.2340\/00015555-3494","article-title":"Melanoma Risk and Melanocyte Biology","volume":"100","author":"Bertrand","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Curioni-Fontecedro, A., Pitocco, R., Schoenewolf, N.L., Holzmann, D., Soldini, D., Dummer, R., Calvieri, S., Moch, H., Fitsche, A., and Mihic-Probst, D. (2019). Erratum to \u201cintratumoral heterogeneity of MAGE-C1\/CT7 and MAGE-C2\/CT10 expression in mucosal melanoma\u201d. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/5256364"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1111\/cas.14195","article-title":"Variable indoleamine 2,3-dioxygenase expression in acral\/mucosal melanoma and its possible link to immunotherapy","volume":"110","author":"Iga","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3747\/co.27.5933","article-title":"Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: An Ontario Health (Cancer Care Ontario) clinical practice guideline","volume":"27","author":"Petrella","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Donizy, P., Wu, C.-L., Mull, J., Fujimoto, M., Ch\u0142opik, A., Peng, Y., Shalin, S.C., Selim, M.A., Puig, S., and Fern\u00e1ndez-Figueras, M.T. (2020). Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas. Cells, 9.","DOI":"10.3390\/cells9051135"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000506327","article-title":"Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy","volume":"13","author":"Fujimura","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nishiya, A.T., Nagamine, M.K., Da Fonseca, I.I.M., Miraldo, A.C., Scattone, N.V., Guerra, J.L., Xavier, J.G., Santos, M., Gomes, C.O.M.D.S., and Ward, J.M. (2020). Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas. Toxins, 12.","DOI":"10.3390\/toxins12030157"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","article-title":"Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4","volume":"47","author":"Seban","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s12105-020-01158-8","article-title":"Variable Expression of S100 Protein in Sinonasal Malignant Mucosal Melanoma: A Potential Diagnostic Pitfall","volume":"14","author":"Xu","year":"2020","journal-title":"Head Neck Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semdp.2015.10.005","article-title":"Uveal melanoma","volume":"33","author":"Kashyap","year":"2016","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_19","unstructured":"Mitre, V., Heym, K., Clark, G.D., and Venkatramani, R. (2019). Neurocutaneous Melanocytosis and Leptomeningeal Melanoma. J. Pediatr. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/ijc.IJC_612_17","article-title":"Clinicopathological study of malignant melanoma in a regional cancer center","volume":"55","author":"Besra","year":"2018","journal-title":"Indian J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-018-0675-0","article-title":"Mucosal Melanoma: A Literature Review","volume":"20","author":"Yde","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1634\/theoncologist.2010-0067","article-title":"Mucosal Melanomas: A Case-Based Review of the Literature","volume":"15","author":"Seetharamu","year":"2010","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-3-319-22539-5_13","article-title":"Mucosal Melanoma: Epidemiology, Biology and Treatment","volume":"167","author":"Spencer","year":"2015","journal-title":"Cancer Treat. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaad.2006.06.017","article-title":"Primary mucosal melanoma","volume":"56","author":"Patrick","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.5858\/2009-0441-RAR.1","article-title":"Ocular melanoma","volume":"134","author":"Laver","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0039-6109(02)00098-1","article-title":"Ocular melanoma","volume":"83","author":"Char","year":"2003","journal-title":"Surg. Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1590\/abd1806-4841.20153528","article-title":"Study of the histopathological types of cutaneous melanoma in Palmas-TO from 2001 to 2011","volume":"90","author":"Fernandes","year":"2015","journal-title":"An. Bras. de Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Guy","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_31","first-page":"116","article-title":"An updated review of mucosal melanoma: Survival meta-analysis","volume":"11","author":"Hahn","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/lary.27465","article-title":"Optimal resection margin for head and neck cutaneous melanoma","volume":"129","author":"Han","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cayrefourcq, L., De Roeck, A., Garcia, C., Stoebner, P.-E., Fichel, F., Garima, F., Perriard, F., Daures, J.-P., Meunier, L., and Alix-Panabi\u00e8res, C. (2019). S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells. Cells, 8.","DOI":"10.3390\/cells8070755"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s00726-012-1409-5","article-title":"Protein and non-protein biomarkers in melanoma: A critical update","volume":"43","author":"Tandler","year":"2012","journal-title":"Amino Acids"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Belter, B., Haase-Kohn, C., and Pietzsch, J. (2017). Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective. Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/mmt-2016-0013","article-title":"PD-L1 in melanoma: Facts and myths","volume":"3","author":"Merelli","year":"2016","journal-title":"Melanoma Manag."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4161\/21645515.2014.983409","article-title":"PD-1 and PD-L1 antibodies for melanoma","volume":"10","author":"Tsai","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19830301)51:5<840::AID-CNCR2820510516>3.0.CO;2-7","article-title":"LDH and melanoma","volume":"51","author":"Finck","year":"1983","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0000000000000520","article-title":"Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: A systematic review and meta-analysis","volume":"29","author":"Petrelli","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1148\/radiol.13130776","article-title":"Metastatic melanoma: Lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab","volume":"270","author":"Gray","year":"2014","journal-title":"Radiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4065\/mcp.2011.0287","article-title":"Circulating Serologic and Molecular Biomarkers in Malignant Melanoma","volume":"86","author":"Palmer","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_44","first-page":"47","article-title":"Circulating Biomarkers in Malignant Melanoma","volume":"69","author":"Alegre","year":"2015","journal-title":"Int. Rev. Cytol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","article-title":"Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies","volume":"54","author":"Petrelli","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_46","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/260643","article-title":"A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients","volume":"2012","author":"Vereecken","year":"2012","journal-title":"Dermatol. Res. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6601197","article-title":"Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: A clinical follow-up study of 110 patients","volume":"89","author":"Savoia","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/CMR.0b013e328054c667","article-title":"Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients","volume":"17","author":"Quaglino","year":"2007","journal-title":"Melanoma Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fonc.2014.00383","article-title":"Evaluating biomarkers in melanoma","volume":"4","author":"Karagiannis","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000301","article-title":"PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy","volume":"24","author":"Cottrell","year":"2018","journal-title":"Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 Blockade in Cancer Immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2013.08.002","article-title":"Targeting the PD1\/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities","volume":"89","author":"Merelli","year":"2014","journal-title":"Crit. Rev. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/mmt-2017-0018","article-title":"Anti-PD-1 and PD-L1 antibodies in metastatic melanoma","volume":"4","author":"Simeone","year":"2017","journal-title":"Melanoma Manag."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2014","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12254-016-0292-2","article-title":"PD-L1 testing, fit for routine evaluation? From a pathologist\u2019s point of view","volume":"9","author":"Hutarew","year":"2016","journal-title":"Memo"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fonc.2018.00270","article-title":"Biomarkers for Immune Checkpoint Inhibitors in Melanoma","volume":"8","author":"Kitano","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.bbamcr.2008.11.009","article-title":"S100B\u2019s double life: Intracellular regulator and extracellular signal","volume":"1793","author":"Donato","year":"2009","journal-title":"Biochim. et Biophys. Acta (BBA) Bioenerg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27487","DOI":"10.1074\/jbc.M110.155382","article-title":"The Calcium-binding Protein S100B Down-regulates p53 and Apoptosis in Malignant Melanoma","volume":"285","author":"Lin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clinbiochem.2004.05.012","article-title":"S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma","volume":"37","author":"Harpio","year":"2004","journal-title":"Clin. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000011989","article-title":"S100B protein detection in serum is a significant prognostic factor in metastatic melanoma","volume":"56","author":"Hauschild","year":"1999","journal-title":"Oncology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejca.2010.10.005","article-title":"Prognostic value of serial blood S100B determinations in stage IIB\u2013III melanoma patients: A corollary study to EORTC trial 18952","volume":"47","author":"Bouwhuis","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","article-title":"S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies","volume":"119","author":"Wagner","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_66","first-page":"1","article-title":"Heterogeneity in Melanoma","volume":"167","author":"Shannan","year":"2015","journal-title":"Infect. Complicat. Cancer Patients"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.hoc.2018.09.005","article-title":"Cutaneous Melanoma\u2014A Review in Detection, Staging, and Management","volume":"33","author":"Hartman","year":"2019","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"ImmunoTargets Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 inhibitors: Molecular activity and resistance mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_73","first-page":"212515","article-title":"Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: A case of long-term complete response after treatment cessation","volume":"7","author":"Brugnara","year":"2018","journal-title":"Drugs Context"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.2147\/OTT.S147438","article-title":"Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: A meta-analysis","volume":"10","author":"Chen","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CCO.0000000000000610","article-title":"Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting","volume":"32","author":"Herrscher","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013Mutant Advanced Melanoma Treated with Vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1006\/geno.1994.1517","article-title":"Three Genes in the Human MHC Class III Region near the Junction with the Class II: Gene for Receptor of Advanced Glycosylation End Products, PBX2 Homeobox Gene and a Notch Homolog, Human Counterpart of Mouse Mammary Tumor Gene int-3","volume":"23","author":"Sugaya","year":"1994","journal-title":"Genomics"},{"key":"ref_87","first-page":"D1151","article-title":"Receptor for age (RAGE) is a gene within the major histocompatibility class III region: Implications for host response mechanisms in homeostasis and chronic disease","volume":"6","author":"Schmidt","year":"2001","journal-title":"Front. Biosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbrc.2006.04.077","article-title":"Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris","volume":"347","author":"Ostendorp","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4161\/cam.4.2.12430","article-title":"Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye?","volume":"4","author":"Hubert","year":"2010","journal-title":"Cell Adhes. Migr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.gene.6363865","article-title":"How RAGE turns in rage","volume":"3","author":"Verweij","year":"2002","journal-title":"Genes Immun."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wei, W., Lampe, L., Park, S., Vangara, B.S., Waldo, G.S., Cabantous, S., Subaran, S.S., Yang, N., Lakatta, E.G., and Lin, L. (2012). Disulfide Bonds within the C2 Domain of RAGE Play Key Roles in Its Dimerization and Biogenesis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050736"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.str.2016.06.021","article-title":"Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling","volume":"24","author":"Xue","year":"2016","journal-title":"Structure"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","article-title":"Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins","volume":"267","author":"Neeper","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"40762","DOI":"10.1074\/jbc.M110.169276","article-title":"The 1.5 \u00c5 Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE) Ectodomains Reveals Unique Features Determining Ligand Binding","volume":"285","author":"Park","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","article-title":"RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100\/calgranulin polypeptides","volume":"97","author":"Hofmann","year":"1999","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","article-title":"A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)","volume":"22","author":"Raucci","year":"2008","journal-title":"FASEB J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2008.02.163","article-title":"Calcium-regulated intramembrane proteolysis of the RAGE receptor","volume":"370","author":"Galichet","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1096\/fj.08-117739","article-title":"Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene","volume":"23","author":"Kalea","year":"2009","journal-title":"FASEB J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0169-328X(99)00174-6","article-title":"cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein","volume":"71","author":"Malherbe","year":"1999","journal-title":"Mol. Brain Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1042\/bj20021371","article-title":"Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury","volume":"370","author":"Yonekura","year":"2003","journal-title":"Biochem. J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbaexp.2003.08.008","article-title":"Tissue-specific expression patterns of the RAGE receptor and its soluble forms\u2014A result of regulated alternative splicing?","volume":"1630","author":"Schlueter","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.gene.2008.10.027","article-title":"Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms","volume":"434","author":"Sterenczak","year":"2009","journal-title":"Gene"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Jules, J., Maiguel, D., and Hudson, B.I. (2013). Alternative Splicing of the RAGE Cytoplasmic Domain Regulates Cell Signaling and Function. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078267"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"23137","DOI":"10.1074\/jbc.M110.133827","article-title":"Homodimerization Is Essential for the Receptor for Advanced Glycation End Products (RAGE)-mediated Signal Transduction","volume":"285","author":"Zong","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/sj.emboj.7601805","article-title":"Structural and functional insights into RAGE activation by multimeric S100B","volume":"26","author":"Ostendorp","year":"2007","journal-title":"EMBO J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"27255","DOI":"10.1074\/jbc.M801622200","article-title":"Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE)","volume":"283","author":"Xie","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.str.2011.02.013","article-title":"Advanced Glycation End Product Recognition by the Receptor for AGEs","volume":"19","author":"Xue","year":"2011","journal-title":"Structure"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1021\/cb4001553","article-title":"Stable RAGE-Heparan Sulfate Complexes Are Essential for Signal Transduction","volume":"8","author":"Xu","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Sitkiewicz, E., Tarnowski, K., Pozna\u0144ski, J., Kulma, M., and Dadlez, M. (2013). Oligomerization Interface of RAGE Receptor Revealed by MS-Monitored Hydrogen Deuterium Exchange. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076353"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56993-9","article-title":"Enhanced oligomerization of full-length RAGE by synergy of the interaction of its domains","volume":"9","author":"Moysa","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1074\/jbc.M608888200","article-title":"Hexameric Calgranulin C (S100A12) Binds to the Receptor for Advanced Glycated End Products (RAGE) Using Symmetric Hydrophobic Target-binding Patches","volume":"282","author":"Xie","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1111\/febs.12556","article-title":"Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products","volume":"280","author":"Yatime","year":"2013","journal-title":"FEBS J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.str.2010.05.017","article-title":"Structural Basis for Ligand Recognition and Activation of RAGE","volume":"18","author":"Koch","year":"2010","journal-title":"Structure"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Sessa, L., Gatti, E., Zeni, F., Antonelli, A., Catucci, A., Koch, M., Pompilio, G., Fritz, G., Raucci, A., and Bianchi, M.E. (2014). The Receptor for Advanced Glycation End-Products (RAGE) Is Only Present in Mammals, and Belongs to a Family of Cell Adhesion Molecules (CAMs). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086903"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.bbapap.2014.06.017","article-title":"Interaction of S100A13 with C2 domain of receptor for advanced glycation end products (RAGE)","volume":"1844","author":"Rani","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Proteins Proteom."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbamcr.2012.10.021","article-title":"RAGE in tissue homeostasis, repair and regeneration","volume":"1833","author":"Sorci","year":"2013","journal-title":"Biochim. et Biophys. Acta (BBA) Bioenerg."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/jcsm.12350","article-title":"RAGE in the pathophysiology of skeletal muscle","volume":"9","author":"Riuzzi","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fcvm.2018.00163","article-title":"S100\/RAGE-Mediated Inflammation and Modified Cholesterol Lipoproteins as Mediators of Osteoblastic Differentiation of Vascular Smooth Muscle Cells","volume":"5","author":"Chellan","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00249-017-1227-5","article-title":"Lateral diffusion and signaling of receptor for advanced glycation end-products (RAGE): A receptor involved in chronic inflammation","volume":"47","author":"Syed","year":"2017","journal-title":"Eur. Biophys. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"11957","DOI":"10.1021\/acs.jafc.8b04819","article-title":"Tea polypeptide ameliorates diabetic nephropathy through RAGE and NF-\u03baB signaling pathway in type 2 diabetes mice","volume":"66","author":"Deng","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1535370219840981","article-title":"Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model","volume":"244","author":"Hongwei","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2174\/156652407783220705","article-title":"RAGE, Diabetes, and the Nervous System","volume":"7","author":"Toth","year":"2007","journal-title":"Curr. Mol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jpi.12194","article-title":"Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE\/NF-K B\/JNK signaling pathway in aging mouse model","volume":"58","author":"Ali","year":"2015","journal-title":"J. Pineal Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s12035-017-0419-4","article-title":"RAGE-TLR Crosstalk Sustains Chronic Inflammation in Neurodegeneration","volume":"55","author":"Brokos","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neubiorev.2015.12.006","article-title":"RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis","volume":"62","author":"Ray","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1073\/pnas.1522288113","article-title":"Critical role of RAGE and HMGB1 in inflammatory heart disease","volume":"113","author":"Bangert","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2174\/13816128113199990475","article-title":"Role of AGEs-RAGE system in cardiovascular disease","volume":"20","author":"Fukami","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1007\/s00018-019-03204-3","article-title":"Therapeutic potential of vitamin D in AGE\/RAGE-related cardiovascular diseases","volume":"76","author":"Lee","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_129","first-page":"1","article-title":"Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","article-title":"HMGB1 and RAGE in Inflammation and Cancer","volume":"28","author":"Sims","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1016\/j.bbadis.2015.09.022","article-title":"The role of S100 proteins and their receptor RAGE in pancreatic cancer","volume":"1852","author":"Leclerc","year":"2015","journal-title":"Biochim. et Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/labinvest.3780116","article-title":"Interaction of the Receptor for Advanced Glycation End Products (RAGE) with Transthyretin Triggers Nuclear Transcription Factor kB (NF-kB) Activation","volume":"80","author":"Sousa","year":"2000","journal-title":"Lab. Investig."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1084\/jem.20030800","article-title":"The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment","volume":"198","author":"Chavakis","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2012.02.001","article-title":"RAGE binds C1q and enhances C1q-mediated phagocytosis","volume":"274","author":"Ma","year":"2012","journal-title":"Cell. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.4049\/jimmunol.1000863","article-title":"Complement C3a, CpG Oligos, and DNA\/C3a Complex Stimulate IFN-\u03b1 Production in a Receptor for Advanced Glycation End Product-Dependent Manner","volume":"185","author":"Ruan","year":"2010","journal-title":"J. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-2000-13204","article-title":"RAGE: A Multiligand Receptor Contributing to the Cellular Response in Diabetic Vasculopathy and Inflammation","volume":"26","author":"Schmidt","year":"2000","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","article-title":"Understanding RAGE, the receptor for advanced glycation end products","volume":"83","author":"Bierhaus","year":"2005","journal-title":"J. Mol. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jemt.10296","article-title":"Intracellular and extracellular roles of S100 proteins","volume":"60","author":"Donato","year":"2003","journal-title":"Microsc. Res. Tech."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/156652413804486214","article-title":"Functions of S100 proteins","volume":"13","author":"Donato","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejso.2007.04.009","article-title":"A review of the S100 proteins in cancer","volume":"34","author":"Salama","year":"2008","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Leclerc, E. (2011). The Roles of S100 Proteins and RAGE in Melanoma. Breakthroughs in Melanoma Research, IntechOpen.","DOI":"10.5772\/18899"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"31317","DOI":"10.1074\/jbc.M703951200","article-title":"S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor for Advanced Glycation End Products) Immunoglobulin Domains","volume":"282","author":"Leclerc","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_143","first-page":"400","article-title":"S100 protein is present in cultured human malignant melanomas","volume":"286","author":"Gaynor","year":"1980","journal-title":"Nat. Cell Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CMR.0000000000000512","article-title":"Expression and clinical significance of S100 family genes in patients with melanoma","volume":"29","author":"Xiong","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_145","first-page":"1296","article-title":"Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH","volume":"22","author":"Karonidis","year":"2017","journal-title":"J. B. U. ON. Off. J. Balk. Union Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biocel.2014.10.001","article-title":"The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors","volume":"57","author":"Meghnani","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"10539","DOI":"10.1074\/jbc.274.15.10539","article-title":"Calcium-dependent interaction of S100B with the C-terminal domain of the tumor suppressor p53","volume":"274","author":"Delphin","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1073\/pnas.89.23.11627","article-title":"Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein","volume":"89","author":"Baudier","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"35037","DOI":"10.1074\/jbc.M104379200","article-title":"Inhibition of p53 Transcriptional Activity by the S100B Calcium-binding Protein","volume":"276","author":"Lin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2005.080390","article-title":"Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions","volume":"90","author":"Keijser","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CMR.0b013e3283350554","article-title":"Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours","volume":"20","author":"Sviatoha","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_152","first-page":"201","article-title":"Measuring Binding of S100 Proteins to RAGE by Surface Plasmon Resonance","volume":"963","author":"Leclerc","year":"2012","journal-title":"Adv. Struct. Saf. Stud."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.biocel.2016.07.014","article-title":"The characterization of a novel S100A1 binding site in the N-terminus of TRPM1","volume":"78","author":"Jirku","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Khan, I., Yuan, T., Chou, R.-H., and Yu, C. (2019). S100A4 inhibits cell proliferation by interfering with the S100A1-RAGE V domain. PLoS ONE, 14.","DOI":"10.1101\/391136"},{"key":"ref_155","first-page":"28","article-title":"RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells","volume":"28","author":"Leclerc","year":"2009","journal-title":"Gen. Physiol. Biophys."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9","article-title":"Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma","volume":"74","author":"Maelandsmo","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1600-0560.2007.00953.x","article-title":"Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors","volume":"35","author":"Nonaka","year":"2008","journal-title":"J. Cutan. Pathol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.18632\/oncotarget.1908","article-title":"RAGE mediates S100A4-induced cell motility via MAPK\/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis","volume":"5","author":"Dahlmann","year":"2014","journal-title":"Oncotarget"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jcmm.12808","article-title":"Interaction of extracellular S100A4 with RAGE prompts prometastatic activation of A375 melanoma cells","volume":"20","author":"Herwig","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.MP.0000071128.67149.FD","article-title":"S100A6 Protein Expression is Different in Spitz Nevi and Melanomas","volume":"16","author":"McNutt","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.tranon.2017.03.002","article-title":"Affinity Proteomics Exploration of Melanoma Identifies Proteins in Serum with Associations to T-Stage and Recurrence","volume":"10","author":"Fredolini","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.1074\/jbc.M109.083550","article-title":"Lack of an Endogenous Anti-inflammatory Protein in Mice Enhances Colonization of B16F10 Melanoma Cells in the Lungs","volume":"285","author":"Saha","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/ijc.31945","article-title":"exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8\/A9-induced lung tropic cancer metastasis","volume":"144","author":"Kinoshita","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s40425-019-0828-1","article-title":"Tumor microenvironment-derived S100A8\/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies","volume":"7","author":"Wagner","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/modpathol.2010.54","article-title":"S100A13 is a new angiogenic marker in human melanoma","volume":"23","author":"Massi","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"22544","DOI":"10.1074\/jbc.M100546200","article-title":"S100A13 participates in the release of fibroblast growth factor 1 in response to heat shock in vitro","volume":"276","author":"Landriscina","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/bjc.2014.169","article-title":"Proteomics analysis of melanoma metastases: Association between S100A13 expression and chemotherapy resistance","volume":"110","author":"Azimi","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/aps.2012.185","article-title":"Safflor yellow A protects neonatal rat cardiomyocytes against anoxia\/reoxygenation injury in vitro","volume":"34","author":"Duan","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/1346-8138.12323","article-title":"Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma","volume":"40","author":"Zhu","year":"2013","journal-title":"J. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2559.2004.01800.x","article-title":"Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies","volume":"44","author":"Udvarhelyi","year":"2004","journal-title":"Histopathology"},{"key":"ref_171","first-page":"636","article-title":"Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B","volume":"31","author":"Palomares","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_172","first-page":"158","article-title":"Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients","volume":"14","author":"Gebhardt","year":"2016","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.bbadis.2014.02.013","article-title":"RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line","volume":"1842","author":"Meghnani","year":"2014","journal-title":"Biochim. et Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1600-0625.2012.01565.x","article-title":"Role of TRPM in melanocytes and melanoma","volume":"21","author":"Guo","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2353\/ajpath.2010.090526","article-title":"S100A4 and metastasis: A small actor playing many roles","volume":"176","author":"Boye","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1074\/jbc.R500017200","article-title":"S100A4, a Mediator of Metastasis","volume":"281","author":"Garrett","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"73219","DOI":"10.18632\/oncotarget.18016","article-title":"S100A4 in cancer progression and metastasis: A systematic review","volume":"8","author":"Fei","year":"2017","journal-title":"Oncotarget"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.bbrc.2016.07.009","article-title":"Extracellular S100A4 affects endothelial cell integrity and stimulates transmigration of A375 melanoma cells","volume":"477","author":"Herwig","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1600-0560.2001.028005229.x","article-title":"S100A6 expression in fibrohistiocytic lesions","volume":"28","author":"Fullen","year":"2001","journal-title":"J. Cutan. Pathol."},{"key":"ref_180","first-page":"1291","article-title":"Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice","volume":"52","author":"Weterman","year":"1992","journal-title":"Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000363097","article-title":"S100A6 and c-Kit-Positive Spindle Cell Melanoma of the Dorsal Foot","volume":"6","author":"Mitamura","year":"2014","journal-title":"Case Rep. Dermatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.tranon.2020.100753","article-title":"S100 Soil Sensor Receptors and Molecular Targeting Therapy Against Them in Cancer Metastasis","volume":"13","author":"Tomonobu","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/0008-5472.CAN-11-3843","article-title":"S100A9 Is a Novel Ligand of EMMPRIN That Promotes Melanoma Metastasis","volume":"73","author":"Hibino","year":"2013","journal-title":"Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10585-016-9801-2","article-title":"MCAM, as a novel receptor for S100A8\/A9, mediates progression of malignant melanoma through prominent activation of NF-\u03baB and ROS formation upon ligand binding","volume":"33","author":"Ruma","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2019.03.023","article-title":"Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8\/A9 binding in the original skin lesion","volume":"452","author":"Chen","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-011-1062-5","article-title":"Calcium-binding protein S100P and cancer: Mechanisms and clinical relevance","volume":"138","author":"Jiang","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/modpathol.3800300","article-title":"Ezrin in primary cutaneous melanoma","volume":"18","author":"Ilmonen","year":"2004","journal-title":"Mod. Pathol."},{"key":"ref_189","first-page":"2442","article-title":"Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma","volume":"42","author":"Vaheri","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Vicentino, A.R.R., Carneiro, V.C., Allonso, D., Guilherme, R.D.F., Benjamim, C.F., Dos Santos, H.A.M., Xavier, F., Pyrrho, A.D.S., Gomes, J.D.A.S., and Fonseca, M.D.C. (2018). Emerging Role of HMGB1 in the Pathogenesis of Schistosomiasis Liver Fibrosis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01979"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1139\/O08-110","article-title":"The dynamics of HMG protein-chromatin interactions in living cells","volume":"87","author":"Gerlitz","year":"2009","journal-title":"Biochem. Cell Biol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.embor.embor741","article-title":"Priming the nucleosome: A role for HMGB proteins?","volume":"4","author":"Travers","year":"2003","journal-title":"EMBO Rep."},{"key":"ref_193","first-page":"14","article-title":"A New Group of Chromatin-Associated Proteins with a High Content of Acidic and Basic Amino Acids","volume":"38","author":"Goodwin","year":"1973","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbagrm.2009.11.014","article-title":"High-mobility group box 1 and cancer","volume":"1799","author":"Tang","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA) Bioenerg."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1189\/jlb.72.6.1084","article-title":"HMGB1 as a DNA-binding cytokine","volume":"72","author":"Andersson","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/blood-2006-09-044776","article-title":"A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA","volume":"110","author":"Ivanov","year":"2007","journal-title":"Blood"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"19726","DOI":"10.1016\/S0021-9258(19)36575-5","article-title":"Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation","volume":"268","author":"Parkkinen","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2796.2003.01301.x","article-title":"Amphoterin as an extracellular regulator of cell motility: From discovery to disease","volume":"255","author":"Huttunen","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.1074\/jbc.M509436200","article-title":"The Amphoterin (HMGB1)\/Receptor for Advanced Glycation End Products (RAGE) Pair Modulates Myoblast Proliferation, Apoptosis, Adhesiveness, Migration, and Invasiveness","volume":"281","author":"Riuzzi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3892\/ol.2011.459","article-title":"High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues","volume":"3","author":"Todorova","year":"2011","journal-title":"Oncol. Lett."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/j.1349-7006.2008.00894.x","article-title":"High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma","volume":"99","author":"Sasahira","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_202","first-page":"191","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"29914","DOI":"10.1038\/srep29914","article-title":"Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages","volume":"6","author":"Huber","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"25752","DOI":"10.1074\/jbc.270.43.25752","article-title":"The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin: Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system","volume":"270","author":"Hori","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/labinvest.2015.44","article-title":"High-mobility group box 1 accelerates lipopolysaccharide-induced lung fibroblast proliferation in vitro: Involvement of the NF-\u03baB signaling pathway","volume":"95","author":"Li","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes","volume":"192","author":"Andersson","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00011-006-6112-0","article-title":"HMGB1 modulates inflammatory responses in LPS-activated macrophages","volume":"56","year":"2007","journal-title":"Inflamm. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.113.4.611","article-title":"Regulation of cell migration by amphoterin","volume":"113","author":"Fages","year":"2000","journal-title":"J. Cell Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1083\/jcb.152.6.1197","article-title":"The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells","volume":"152","author":"Degryse","year":"2001","journal-title":"J. Cell Biol."},{"key":"ref_210","first-page":"1","article-title":"Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma","volume":"2013","author":"Tang","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jid.2018.05.035","article-title":"HMGB1\/RAGE Mediates UVB-Induced Secretory Inflammatory Response and Resistance to Apoptosis in Human Melanocytes","volume":"139","author":"Zhang","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1158\/0008-5472.CAN-18-3134","article-title":"Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kappaB contributes to UV radiation-induced immune suppression","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/anticanres.11282","article-title":"Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review","volume":"37","author":"Nguyen","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1039\/c1fo10026b","article-title":"Inhibition of advanced glycation endproduct formation by foodstuffs","volume":"2","author":"Wu","year":"2011","journal-title":"Food Funct."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s001250051591","article-title":"Advanced glycation end-products: A review","volume":"44","author":"Singh","year":"2001","journal-title":"Diabetologia"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.dsx.2016.09.009","article-title":"Activation of the receptor for advanced glycation end products and consequences on health","volume":"11","author":"Wautier","year":"2017","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00003495-200464050-00001","article-title":"Advanced glycation endproduct crosslinking in the cardiovascular system: Potential therapeutic target for cardiovascular disease","volume":"64","author":"Zieman","year":"2004","journal-title":"Drugs"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.acc.2015.07.005","article-title":"Glycated Serum Albumin and AGE Receptors","volume":"72","author":"Vetter","year":"2015","journal-title":"Adv. Clin. Chem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.0022-202X.2004.22218.x","article-title":"Regulation of Human Melanoma Growth and Metastasis by AGE\u2013AGE Receptor Interactions","volume":"122","author":"Abe","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.mehy.2005.01.015","article-title":"Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients","volume":"64","author":"Yamagishi","year":"2005","journal-title":"Med. Hypotheses"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2119\/molmed.2017.00099","article-title":"RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice","volume":"23","author":"Nakamara","year":"2017","journal-title":"Mol. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/labinvest.2014.5","article-title":"DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice","volume":"94","author":"Ojima","year":"2014","journal-title":"Lab. Investig."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tjog.2018.02.008","article-title":"HMGB1-RAGE signaling pathway in pPROM","volume":"57","author":"Yan","year":"2018","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/onc.2016.324","article-title":"Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis","volume":"36","author":"Kwak","year":"2017","journal-title":"Oncogene"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/07853890902806576","article-title":"Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation","volume":"41","author":"Yan","year":"2009","journal-title":"Ann. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","article-title":"Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease","volume":"32","author":"Srikanth","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/156652407783220697","article-title":"RAGE and RAGE ligands in cancer","volume":"7","author":"Logsdon","year":"2007","journal-title":"Curr. Mol. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11914-019-00499-w","article-title":"RAGE Signaling in Skeletal Biology","volume":"17","author":"Plotkin","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/1389450119666180820105956","article-title":"Inhibition of RAGE Axis Signaling: A Pharmacological Challenge","volume":"20","author":"Rojas","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"19919","DOI":"10.1074\/jbc.274.28.19919","article-title":"Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways","volume":"274","author":"Huttunen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.21.6.905","article-title":"Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E\u2013Null Mice","volume":"21","author":"Kislinger","year":"2001","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1172\/JCI200317115","article-title":"Central role of RAGE-dependent neointimal expansion in arterial restenosis","volume":"111","author":"Sakaguchi","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M801465200","article-title":"Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42","volume":"283","author":"Hudson","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Sakaguchi, M., Murata, H., Yamamoto, K.-I., Ono, T., Sakaguchi, Y., Motoyama, A., Hibino, T., Kataoka, K., and Huh, N.-H. (2011). TIRAP, an Adaptor Protein for TLR2\/4, Transduces a Signal from RAGE Phosphorylated upon Ligand Binding. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023132"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1152\/physrev.00006.2017","article-title":"The Arp2\/3 regulatory system and its deregulation in cancer","volume":"98","author":"Molinie","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y","article-title":"Role of receptor for advanced glycation end-product (RAGE) and the JAK\/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells","volume":"81","author":"Huang","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4161\/auto.20258","article-title":"AGER\/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway","volume":"8","author":"Kang","year":"2012","journal-title":"Autophagy"},{"key":"ref_238","first-page":"2169","article-title":"Advanced glycation endproducts induce apoptosis of endothelial progenitor cells by activating receptor RAGE and NADPH oxidase\/JNK signaling axis","volume":"8","author":"Chen","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_239","first-page":"354","article-title":"Blockade of RAGE\u2013amphoterin signalling suppresses tumour growth and metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"31740","DOI":"10.1074\/jbc.274.44.31740","article-title":"N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression","volume":"274","author":"Kislinger","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.272.28.17810","article-title":"Activation of the Receptor for Advanced Glycation End Products Triggers a p21ras-dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress","volume":"272","author":"Lander","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neurobiolaging.2008.05.017","article-title":"S100B\/RAGE-dependent activation of microglia via NF-kappa B and AP-1 Co-regulation of COX-2 expression by S100B, IL-1 beta and TNF-alpha","volume":"31","author":"Bianchi","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"38635","DOI":"10.1074\/jbc.M202515200","article-title":"Receptor for Advanced Glycation End Products (RAGE) Signaling Induces CREB-dependent Chromogranin Expression during Neuronal Differentiation","volume":"277","author":"Huttunen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/DDDT.S201818","article-title":"The molecular mechanisms of Aloin induce gastric cancer cells apoptosis by targeting High Mobility Group Box 1","volume":"13","author":"Tao","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1042\/BST0330891","article-title":"Rho GTPases and the control of cell behaviour","volume":"33 Pt 5","author":"Hall","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/onc.2009.2","article-title":"Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates","volume":"28","author":"Yamazaki","year":"2009","journal-title":"Oncogene"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/thy.2014.0257","article-title":"RAGE Mediates the Pro-Migratory Response of Extracellular S100A4 in Human Thyroid Cancer Cells","volume":"25","author":"Medapati","year":"2015","journal-title":"Thyroid"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1083\/jcb.200802081","article-title":"Cell motility through plasma membrane blebbing","volume":"181","author":"Fackler","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tcb.2005.11.003","article-title":"Dynamic modes of the cortical actomyosin gel during cell locomotion and division","volume":"16","author":"Paluch","year":"2006","journal-title":"Trends Cell Biol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cub.2006.05.065","article-title":"ROCK- and Myosin-Dependent Matrix Deformation Enables Protease-Independent Tumor-Cell Invasion In Vivo","volume":"16","author":"Wyckoff","year":"2006","journal-title":"Curr. Biol."},{"key":"ref_251","first-page":"239","article-title":"RAGE-Mediated Cell Signaling","volume":"963","author":"Rouhiainen","year":"2012","journal-title":"Adv. Struct. Saf. Stud."},{"key":"ref_252","first-page":"1749","article-title":"Oridonin induces apoptosis in oral squamous cell carcinoma probably through the generation of reactive oxygen species and the p38\/JNK MAPK pathway","volume":"52","author":"Oh","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_253","first-page":"E685","article-title":"Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE","volume":"280","author":"Wautier","year":"2001","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1471-4159.2003.01988.x","article-title":"Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs)","volume":"87","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jcp.21852","article-title":"Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions","volume":"221","author":"Perrone","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1242\/jcs.074674","article-title":"RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion","volume":"123","author":"Sbai","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"a000141","DOI":"10.1101\/cshperspect.a000141","article-title":"NF-kappaB as a critical link between inflammation and cancer","volume":"1","author":"Karin","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/BJ20120298","article-title":"Advanced-glycation-end-product-induced formation of immunoproteasomes: Involvement of RAGE and Jak2\/STAT1","volume":"448","author":"Grimm","year":"2012","journal-title":"Biochem. J."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2012.02.014","article-title":"HMGB-1 induces cell motility and alpha 5 beta 1 integrin expression in human chondrosarcoma cells","volume":"322","author":"Tang","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1139\/bcb-2013-0064","article-title":"Expression and subcellular localization of RAGE in melanoma cells","volume":"92","author":"Popa","year":"2014","journal-title":"Biochem. Cell Biol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcancer.2017.10.008","article-title":"Ousting RAGE in melanoma: A viable therapeutic target?","volume":"49","author":"Syed","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","article-title":"Why are tumour blood vessels abnormal and why is it important to know?","volume":"100","author":"Nagy","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1189\/jlb.0306169","article-title":"Cytolytic cells induce HMGB1 release from melanoma cell lines","volume":"81","author":"Ito","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2796.2003.01204.x","article-title":"High mobility group 1 B-box mediates activation of human endothelium","volume":"254","author":"Treutiger","year":"2003","journal-title":"J. Intern. Med."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1006\/bbrc.1996.1180","article-title":"Effect of Advanced Glycosylation End Products on the Induction of Nitric Oxide Synthase in Murine Macrophages","volume":"225","author":"Rojas","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0303-7207(02)00212-5","article-title":"Advanced glycosylation end products induce NF-kappa B dependent NOS expression in RAW 264.7 cells","volume":"194","author":"Wu","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","article-title":"RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages","volume":"61","author":"Kokkola","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imlet.2009.02.011","article-title":"Role of macrophages in tumour progression","volume":"123","author":"Siveen","year":"2009","journal-title":"Immunol. Lett."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/intimm\/dxs051","article-title":"HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells","volume":"24","author":"Wild","year":"2012","journal-title":"Int. Immunol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","article-title":"Immunosuppression associated with chronic inflammation in the tumor microenvironment","volume":"36","author":"Wang","year":"2015","journal-title":"Carcinogenesis"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/8989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:37:48Z","timestamp":1760179068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/8989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":270,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21238989"],"URL":"https:\/\/doi.org\/10.3390\/ijms21238989","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]}}}